Publications & Research

The understanding and treatment of Pulmonary Hypertension is a rapidly growing field and yet there are still many unknowns

At Sydney Pulmonary Hypertension Specialists, we are actively involved in local and international research in this area to further develop our knowledge about this complicated and severe disease.

Current Research

Pulmonary Hypertension Current Research

Pulmonary arterial hypertension (PAH) can be a progressive and severely limiting disease without treatment. The last two decades have seen an enormous improvement in the understanding of the pathological process of PAH and the development of new treatments through research and clinical trials but our knowledge of the best and most effective treatments is still limited.

Combination therapies have been shown to be more effective than single therapies but are currently not funded by the Australian government.

The Sydney Pulmonary Hypertension Specialists are actively involved in clinical research in the area of pulmonary hypertension. This not only enables us to advance knowledge in this field but also allows us access to therapies not currently available to patients in Australia.

As such, you may be invited to consider participating in one these research trials.  You are under no obligation to accept and your treatment will not be affected in any way if you wish to decline.  Participation is free of charge and your travel costs will be reimbursed.

Currently we are running the following trials. Please let us know if you would be interested in participating.

ADVANCE OUTCOMES (APD811-301)

A Study Evaluating the Efficacy and Safety of Ralinepag To Improve Treatment Outcomes in PAH Patients

Enrolment commencing 2019

ADVANCE EXTENSION (APD811-303)

A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label Extensio

FREEDOM 310

A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertensio Receiving Background Oral Monotherapy

Enrolment closed December 2017

FREEDOM 311

An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial        Hypertension - A       Long-Term Follow-Up to Protocol TDE-PH-310

Enrolment commenced February 2016

These international studies are comparing oral treprostinil versus placebo three times a day for   patients who are already on single background therapy.

iNOvation

Inhaled nitric oxide/inopulse® delivery device for use in long-term symptomatic subjects with  pulmonary hypertension and in subjects with pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD)

Commenced Dec 2016

This international trial is for patients with PAH having home oxygen.  It is comparing the addition of placebo to inhaled ambulatory nitric oxide for a minimum of 12 hours per day.

Cardiac 4D flow dynamics on cardiac MRI versus right heart catheterisation

This is a study of looking at four dimensional blood flow dynamics within the pulmonary artery in normal and pulmonary hypertensive patients using cardiac MRI.  A voluntary component of this study will be comparing right heart pressures on right heart catheterisation with the flow dynamics on cardiac MRI. This is a multi institutional study within NSW.

Respiratory muscle training to improve exercise capacity and quality of life in people with pulmonary arterial hypertension

This study is investigating the effects of Respiratory Muscle Training on heart function, exercise capacity and quality of life in people with pulmonary arterial hypertension (PAH). This is a multi institutional study within NSW which is being led by RPA hospital.

Selected Publications

Sydney Pulmonary Hypertension Specialists

Useful Links

PAH Centres

Pulmonary Hypertension Society of Australia and New Zealand

The Thoracic Society of Australia and New Zealand (ANZCOTR)

The International Society for Heart & Lung Transplantation (ISHLT)

Lung Foundation Australia

St Vincents Hospital

Pulmonary Vascular Research Institute (PVRI)

Pulmonary Hypertension Association Australia (PHAA)